V. Serhiyenko, Ludmila Serhiyenko, S. Ajmi, A. Serhiyenko
{"title":"糖尿病心脏自主神经病变:他汀类药物和omega-3多不饱和脂肪酸对血脂和胰岛素抵抗参数的影响","authors":"V. Serhiyenko, Ludmila Serhiyenko, S. Ajmi, A. Serhiyenko","doi":"10.15761/crt.1000274","DOIUrl":null,"url":null,"abstract":"Background: Currently, there is no unified treatment algorithm of cardiac autonomic neuropathy (CAN) in patients with type 2 diabetes mellitus (T2DM). The aim of this study was to investigate the effects of simvastatin (SIM) and ω-3 polyunsaturated fatty acids (ω-3 PUFAs) on blood lipid profile and insulin resistance (IR) in patients with T2DM and definite CAN. Methods: The study involved 72 patients with T2DM and definite CAN. Patients were divided into four groups: 1st received standard hypoglycemic therapy control (n = 15); 2nd (n = 22) – in addition SIM 20 mg/q.d.; 3rd (n = 18) in addition 1 capsule/q.d. of the ω-3 PUFAs; 4th (n = 17) in addition SIM 10 mg/ q.d and 1 capsule/q.d of the ω-3 PUFAs for three months. The concentration of glucose, glycated hemoglobin A1c, immunoreactive insulin (IRI), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG) in the blood were determined. Homeostasis model assessment IR (HOMA-IR), atherogenic coefficient (AC), TG/LDL-C, TG/TC, TG/LDL-C and TG glucose (TyG) were calculated. Results: Prescription of SIM was accompanied by a statistically significant decrease in TC, LDL-C, TG concentrations. In parallel, SIM induced a decrease of AC, TG/HDL-C, increase in HDL-C, and does not affect the IRI, HOMA-IR, TG/LDL-C, TG/TC, TC/LDL-C/HDL-C, TyG. The use of ω-3 PUFAs has contributed to a significant reduction in TG, AC, TG/LDL-C, TG/TC, TG/HDL-C, TyG index, increase in HDL-C, and was not accompanied by changes in IRI content, HOMA-IR, TC, LDL-C, and TC/LDL-C/HDL-C. The combined prescription of SIM and ω-3 PUFAs was accompanied by more pronounced, statistically significant changes in the blood lipid spectrum, as well as a decrease in the IRI and HOMA-IR. Conclusion: Obtained results justify the appropriateness of combined SIM and ω-3 PUFAs prescription to patients with T2DM and definite CAN. *Correspondence to: Victoria A Serhiyenko, Assistant Professor, Department of Endocrinology, Danylo Halytsky Lviv National Medical University, 69, Pekarska Str., 79010, Lviv, Ukraine, Tel: 00380987463315; E-mail: serhiyenkoa@gmail. com; serhiyenkov@gmail.com","PeriodicalId":90808,"journal":{"name":"Clinical research and trials","volume":"59 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Diabetic cardiac autonomic neuropathy: Effects of statins and omega-3 polyunsaturated fatty acids on lipid profile and insulin resistance parameters\",\"authors\":\"V. Serhiyenko, Ludmila Serhiyenko, S. Ajmi, A. Serhiyenko\",\"doi\":\"10.15761/crt.1000274\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Currently, there is no unified treatment algorithm of cardiac autonomic neuropathy (CAN) in patients with type 2 diabetes mellitus (T2DM). The aim of this study was to investigate the effects of simvastatin (SIM) and ω-3 polyunsaturated fatty acids (ω-3 PUFAs) on blood lipid profile and insulin resistance (IR) in patients with T2DM and definite CAN. Methods: The study involved 72 patients with T2DM and definite CAN. Patients were divided into four groups: 1st received standard hypoglycemic therapy control (n = 15); 2nd (n = 22) – in addition SIM 20 mg/q.d.; 3rd (n = 18) in addition 1 capsule/q.d. of the ω-3 PUFAs; 4th (n = 17) in addition SIM 10 mg/ q.d and 1 capsule/q.d of the ω-3 PUFAs for three months. The concentration of glucose, glycated hemoglobin A1c, immunoreactive insulin (IRI), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG) in the blood were determined. Homeostasis model assessment IR (HOMA-IR), atherogenic coefficient (AC), TG/LDL-C, TG/TC, TG/LDL-C and TG glucose (TyG) were calculated. Results: Prescription of SIM was accompanied by a statistically significant decrease in TC, LDL-C, TG concentrations. In parallel, SIM induced a decrease of AC, TG/HDL-C, increase in HDL-C, and does not affect the IRI, HOMA-IR, TG/LDL-C, TG/TC, TC/LDL-C/HDL-C, TyG. The use of ω-3 PUFAs has contributed to a significant reduction in TG, AC, TG/LDL-C, TG/TC, TG/HDL-C, TyG index, increase in HDL-C, and was not accompanied by changes in IRI content, HOMA-IR, TC, LDL-C, and TC/LDL-C/HDL-C. The combined prescription of SIM and ω-3 PUFAs was accompanied by more pronounced, statistically significant changes in the blood lipid spectrum, as well as a decrease in the IRI and HOMA-IR. Conclusion: Obtained results justify the appropriateness of combined SIM and ω-3 PUFAs prescription to patients with T2DM and definite CAN. *Correspondence to: Victoria A Serhiyenko, Assistant Professor, Department of Endocrinology, Danylo Halytsky Lviv National Medical University, 69, Pekarska Str., 79010, Lviv, Ukraine, Tel: 00380987463315; E-mail: serhiyenkoa@gmail. com; serhiyenkov@gmail.com\",\"PeriodicalId\":90808,\"journal\":{\"name\":\"Clinical research and trials\",\"volume\":\"59 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical research and trials\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15761/crt.1000274\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical research and trials","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15761/crt.1000274","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Diabetic cardiac autonomic neuropathy: Effects of statins and omega-3 polyunsaturated fatty acids on lipid profile and insulin resistance parameters
Background: Currently, there is no unified treatment algorithm of cardiac autonomic neuropathy (CAN) in patients with type 2 diabetes mellitus (T2DM). The aim of this study was to investigate the effects of simvastatin (SIM) and ω-3 polyunsaturated fatty acids (ω-3 PUFAs) on blood lipid profile and insulin resistance (IR) in patients with T2DM and definite CAN. Methods: The study involved 72 patients with T2DM and definite CAN. Patients were divided into four groups: 1st received standard hypoglycemic therapy control (n = 15); 2nd (n = 22) – in addition SIM 20 mg/q.d.; 3rd (n = 18) in addition 1 capsule/q.d. of the ω-3 PUFAs; 4th (n = 17) in addition SIM 10 mg/ q.d and 1 capsule/q.d of the ω-3 PUFAs for three months. The concentration of glucose, glycated hemoglobin A1c, immunoreactive insulin (IRI), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG) in the blood were determined. Homeostasis model assessment IR (HOMA-IR), atherogenic coefficient (AC), TG/LDL-C, TG/TC, TG/LDL-C and TG glucose (TyG) were calculated. Results: Prescription of SIM was accompanied by a statistically significant decrease in TC, LDL-C, TG concentrations. In parallel, SIM induced a decrease of AC, TG/HDL-C, increase in HDL-C, and does not affect the IRI, HOMA-IR, TG/LDL-C, TG/TC, TC/LDL-C/HDL-C, TyG. The use of ω-3 PUFAs has contributed to a significant reduction in TG, AC, TG/LDL-C, TG/TC, TG/HDL-C, TyG index, increase in HDL-C, and was not accompanied by changes in IRI content, HOMA-IR, TC, LDL-C, and TC/LDL-C/HDL-C. The combined prescription of SIM and ω-3 PUFAs was accompanied by more pronounced, statistically significant changes in the blood lipid spectrum, as well as a decrease in the IRI and HOMA-IR. Conclusion: Obtained results justify the appropriateness of combined SIM and ω-3 PUFAs prescription to patients with T2DM and definite CAN. *Correspondence to: Victoria A Serhiyenko, Assistant Professor, Department of Endocrinology, Danylo Halytsky Lviv National Medical University, 69, Pekarska Str., 79010, Lviv, Ukraine, Tel: 00380987463315; E-mail: serhiyenkoa@gmail. com; serhiyenkov@gmail.com
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
